If you only read the headline numbers, tesamorelin looks like every other body-composition drug of the moment: fat down, lean mass up. But a meta-analysis published in Obesity Research & Clinical Practice in early 2026 makes a point that gets lost in most tesamorelin research summaries — the compound shifted where fat sat without meaningfully changing what the scales said. So what is tesamorelin actually doing, and why does that distinction matter more than any before-and-after photo? This piece walks through the pooled evidence, the population it comes from, and where tesamorelin sits under Australian regulation.

What is tesamorelin, in one paragraph

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It doesn't supply growth hormone; it prompts the pituitary to release its own in a pattern closer to normal pulsatility. It has been approved by the US FDA since 2010 (as Egrifta) for one indication only — reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. The European Medicines Agency application was withdrawn before approval in 2012, so it has never been EMA-approved. Every claim below comes from that narrow clinical setting unless stated otherwise. You can read the broader profile on our tesamorelin page.

The 2026 meta-analysis: what moved, and what didn't

Badran and colleagues pooled five randomised controlled trials of tesamorelin in HIV-associated lipodystrophy. Against placebo, tesamorelin was associated with:

  • Visceral adipose tissue: mean difference −27.71 cm²
  • Hepatic fat percentage: −4.28%
  • Trunk fat: −1.18 kg
  • Waist circumference: −1.61 cm
  • Lean body mass: +1.42 kg

And the results that didn't reach significance:

  • Subcutaneous adipose tissue: no significant reduction
  • BMI: no significant reduction

That combination is the whole story. Deep abdominal fat and liver fat fell; lean mass rose; the fat you can pinch and the number on the scales largely stayed put. Tesamorelin is best understood as a fat-redistribution agent, not a weight-loss agent — which is a very different proposition to the incretin drugs dominating the conversation elsewhere in our peptides section.

The limb-fat footnote

The same analysis reported a small reduction in limb fat (−0.22 kg). In a population where peripheral lipoatrophy is already part of the syndrome, losing fat from the arms and legs is not a neutral finding. It's small, and it's one pooled estimate, but it's the kind of detail that disappears when a result gets compressed into "reduces fat".

Why this isn't new data

A meta-analysis re-analyses trials that already exist. The tesamorelin RCT base is small, largely funded by the manufacturer, and concentrated in one clinical population studied over 26 to 52 weeks. Pooling five trials sharpens the estimate; it does not extend the evidence to people without HIV, to longer timeframes, or to general obesity. There are no adequately powered trials of tesamorelin for weight loss in the general population.

The liver-fat signal is the more interesting thread

The strongest non-lipodystrophy-adjacent result is Stanley and colleagues' 2019 randomised, double-blind, multicentre trial in The Lancet HIV: 61 participants with HIV and a hepatic fat fraction above 5%, randomised to tesamorelin 2 mg daily or placebo for 12 months. Tesamorelin reduced liver fat and was associated with less fibrosis progression than placebo.

Sixty-one people is a small trial, and the authors themselves called for further work on long-term liver histology. It has not been replicated in a larger cohort, and it has never been tested in metabolic dysfunction-associated steatotic liver disease (MASLD) outside HIV — which is where most of the commercial interest now sits. Treat it as a hypothesis-generating result with an interesting mechanism behind it, not an established use.

The cognition claim: real trial, old result, no follow-through

Tesamorelin's other recurring talking point is cognition. That traces to a genuine randomised controlled trial reported by Baker and colleagues around 2011–2012: 137 completers aged 55–87, split between healthy older adults and people with mild cognitive impairment, self-administering 1 mg daily for 20 weeks. Executive function improved, with a smaller effect on short-term verbal memory.

That is a real finding — but it is now roughly fifteen years old, it was a 20-week study of intermediate cognitive measures rather than clinical dementia outcomes, and it has not been followed by a confirmatory phase 3 programme. A separate phase II crossover trial in ageing people with HIV (NCT02572323) explored the same question. Anyone presenting tesamorelin as a nootropic is extrapolating a long way past one unreplicated trial.

The formulation update most summaries missed

On 25 March 2025 the FDA approved Theratechnologies' supplemental BLA for the F8 formulation, marketed as EGRIFTA WR. It is eight times more concentrated than the original Egrifta, halves the injection volume versus the F4 formulation, and — the practical change — requires reconstitution weekly rather than daily. Pharmacokinetic studies supported bioequivalence to the original formulation.

Note what this is and isn't: a delivery and convenience improvement within the same approved HIV indication. It is not new efficacy data, and it does not expand who the drug is approved for.

Is tesamorelin legal in Australia?

No tesamorelin product is on the Australian Register of Therapeutic Goods. Neither Egrifta nor EGRIFTA WR is a registered medicine here, which means there is no TGA-evaluated product, no approved Australian product information, and nothing that can lawfully be advertised or supplied to consumers as a therapeutic good. Substances of this class are prescription-only; supply outside a lawful prescribing pathway isn't a grey area, it's unapproved supply.

Two further Australian-relevant points:

  • Sport: tesamorelin is a GHRH analogue, and GHRH analogues are prohibited at all times under the WADA Prohibited List. Any athlete under an anti-doping code should treat this as disqualifying regardless of how it was obtained.
  • "Research use only" framing: vials labelled that way are not a legal workaround for human use in Australia, and their contents are not independently verified for identity or purity.

We don't tell readers where to buy anything. If tesamorelin is clinically relevant to you, that conversation belongs with an Australian doctor who knows your history.

The honest summary

Tesamorelin has a narrow, genuinely evidence-backed use: visceral and hepatic fat reduction in HIV-associated lipodystrophy, now supported by a 2026 pooled analysis of five RCTs. It has a small, unreplicated liver-fat trial, a fifteen-year-old cognition signal that was never confirmed, and a lot of marketing built on the gap between those two things. The most useful fact for a general reader is the one the meta-analysis put in plain sight: it changed where fat was, not how much the person weighed.

Want the next evidence breakdown in your inbox? Join the free updates list.

FAQ

What is tesamorelin used for?

Tesamorelin is FDA-approved for one use only: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. All other proposed uses — general weight loss, liver fat outside HIV, cognition — rest on small or unreplicated evidence.

Does tesamorelin cause weight loss?

Not in the way most people mean. The 2026 meta-analysis of five RCTs found significant reductions in visceral and liver fat and an increase in lean mass, but no significant reduction in BMI or subcutaneous fat.

Is tesamorelin legal in Australia?

There is no tesamorelin product on the ARTG, so it isn't an approved medicine in Australia and cannot be lawfully advertised or supplied to consumers. It is also prohibited at all times in sport under the WADA Prohibited List as a GHRH analogue.

Does tesamorelin improve memory?

One randomised trial of 137 older adults, reported around 2011–2012, found improved executive function after 20 weeks of 1 mg daily, with a smaller effect on verbal memory. It has not been confirmed by a larger follow-up trial and is not an approved use.

Sources

This article is independent information, not medical advice. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, was never approved by the EMA, and is not on the ARTG in Australia. Speak to a qualified Australian health practitioner about your own circumstances.